ch.oddb.org
 
Apotheken | Doctor | Drugs | Hospital | Interactions | MiGeL | Registration owner | Services
Ultomiris 300 mg/30 ml, Konzentrat zur Herstellung einer Infusionslösung - 
67278001 Alexion Pharma GmbH
Ultomiris 300 mg/30 ml, Konzentrat zur Herstellung einer Infusionslösung20.01.2020
  20.01.2020
Ravulizumab (L04AA43) 
WHO-DDD 
07.15. 
07.15. 
A  
Yes 
IP 
4035.61Yes
    
10 %4181.60
7680672780016Biotechnologika
  
Composition
ravulizumabum 300 mg, natrii dihydrogenophosphas, dinatrii phosphas, natrii chloridum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 30 ml corresp. natrium 115 mg.
Packungsbestandteile
Concentrate for infusion 
  
 
Active AgentDose
Ravulizumabum300mg / 30ml
BAG: Active AgentDose
Ravulizumabum300 mg
 
Inactive agents
Disodium Phosphate
Sodium Chloride
Natrii Dihydrogenophosphas
Polysorbatum 80
 
Source
Data was imported : 05.09.2024 Swissmedic Registration : Sequence : Product name : Registration owner: : Product group : Index Therapeuticus (BSV) : Medication Code : Date of registration : Valid until : Package number : Show package size : Commercial Form/Unit : Swissmedic categorie. : Active Agents : Composition :
 
2025 ©ywesee GmbH
Settings | Help | FAQ | Login | Contact | Home